ArticleDiscover oncology2025
ZNF432 suppresses endometrial cancer progression by promoting UPF1 ubiquitination and inducing apoptosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is a malignant tumor originating from the uterine epithelial lining and is one of the most common gynecologic malignancies worldwide. Ubiquitination, as a crucial regulatory mechanism in cell physiology, plays a key role in processes such as cell cycle control, DNA repair, and tumorigenesis. UPF1, a critical regulator of ubiquitination, is involved in the development of various diseases, including cancer, due to its influence on mRNA stability and protein degradation. This study aims to identify novel molecular targets related to EC pathogenesis and to explore their mechanisms of action. Through bioinformatics analysis, we identified ZNF432 as a significantly differentially expressed gene in EC tissues. Functional experiments demonstrated that ZNF432 overexpression significantly inhibited EC cell proliferation and induced apoptosis. In in vivo experiments, ZNF432 overexpression significantly suppressed tumor growth in a nude mouse xenograft model. Mechanistically, ZNF432 induced apoptosis by interacting with UPF1 and enhancing its ubiquitination, promoting the degradation of pro-survival factors in EC cells. These findings provide new insights into the molecular mechanisms underlying EC and highlight ZNF432 as a potential therapeutic target, offering promising prospects for the development of novel treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.